Meta-analysis of 24 studies (30,395 patients) in GI cancers: reduced vs standard oxaliplatin exposure showed no significant survival difference (adjuvant colorectal DFS HR 1.06) and less grade ≥3 nerve damage (OR 0.34). Evidence mainly colorectal.
Meta-analysisn = 30,395
Schwengber et al. Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis